Company intelligence / Profile preview

Nantox

Culver City, California, United States

Ownership: Private
Development stage: Other

Overview

Nantox is a biotechnology company focused on developing small molecule therapeutics that modulate aldehyde dehydrogenase (ALDH) enzymes. The company's primary focus is on ALDH2 activators designed to treat conditions related to toxic aldehyde accumulation, such as alcohol flushing syndrome and Fanconi anemia. By targeting the metabolic pathways of aldehydes, Nantox aims to mitigate the risk of esophageal cancer and other complications associated with ALDH2 deficiency. The company operates as part of the broader NantWorks ecosystem, leveraging shared resources to advance its metabolic health pipeline.

Therapeutic areas: PsychiatryHematologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nantox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nantox.

Explore the full profile